Cannovum AG expands Supervisory Board and Medical Advisory Board

Priv. Doz. Dr. med. habil. Philipp Sewerin is the new member of the supervisory board as well as the Medical Advisory Board. Dr. Sewerin is a specialist in internal medicine and rheumatology at the university clinic in Düsseldorf.

Cannovum AG expands Supervisory Board and Medical Advisory Board

 

Berlin, 08th September 2021. Cannovum AG has appointed Priv. Doz. Dr.med. habil. Philipp Sewerin to the supervisory board. In addition to his position on the Supervisory Board, Dr. Sewerin will support Cannovum in an advisory capacity as a scientific expert and new member of the Medical AdvisoryBoard. Dr. Sewerin is a specialist in internal medicine and rheumatology at the university clinic in Düsseldorf. In addition to his clinical activities, he’s engaged in research and clinical trials, particularly on inflammatory rheumatic diseases, is very involved in association work and dedicated to the well-being of patients.

Dr. Sewerin will contribute his in-depth knowledge to Cannovum's Medical Education. This is an advanced training program to support healthcare professionals, for example doctors and pharmacists in setting up cannabis-based therapies and building broader awareness of the medical use of cannabis.

"We are pleased to welcome Dr. Sewerin to the Board of Directors and Medical Advisory Board. His professional expertise in the field of internal medicine is an asset to Cannovum's Medical Education and he will support us in improving the care of medical cannabis patients," says Pia Marten, CEO of Cannovum AG.

The field of internal medicine is a major application area of cannabis-based therapies. In addition to the well-known use of cannabis-based medicines in pain therapy, there is great potential for medical cannabis in the treatment of inflammatory diseases such as rheumatism.

About Cannovum:

Cannovum AG is the first German listed medical cannabis company. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

 

Contact:

Linda Rasch, Head of Communications, Cannovum AG,

Phone+49 30 3982 163 62

linda.rasch@cannovum.com

 

 

Read more
Download pdf

Mehr News

Other
July 2022

Cannovum AG part of the International Expert Hearings on Cannabis Legalization

Cannovum AG has participated in the consultation process of the German government for the legalization of cannabis for Adult-use.

Investment
April 2022

Cannovum AG resolves capital increase from authorized capital excluding subscription rights

The Management Board of Cannovum AG today resolved to increase the share capital.

Investment
February 2022

Cannovum AG launches Cannabis Medical Education Platform

Cannovum Medical Education (CME) is a free, comprehensive virtual continuing education platform for medical cannabis, in which the medical-therapeutic basics of medical cannabis are scientifically prepared.